- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01198912
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial (DOXYPOSTOP)
June 14, 2018 updated by: University Hospital, Ghent
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.
This is a randomized, double blind, placebo controlled, parallel group, study in patients with chronic rhinosinusitis with or without nasal polyps.
The objective is to test the clinical efficacy of long-term low dose oral doxycycline on wound healing quality after endoscopic sinus surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- at least 18 years of age, of either sex and any race
- diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
- Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
- Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
- Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
- Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.
Exclusion Criteria:
- Women must not be pregnant, breast feeding, or premenarcheal.
- Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
- Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
- Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
Patients with the following diseases should be excluded :
- Cystic fibrosis based on positive sweat test or DNA alleles
- Gross immunodeficiency (congenital or acquired)
- congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
- Non-invasive fungal balls and invasive fungal disease
- systemic vasculitis and granulomatous diseases
- Cocaine abuse
- Neoplasia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
during 56 days
|
|
Experimental: doxycycline 100 mg
|
during 56 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Endoscopic evaluation of quality and speed of wound healing
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
nasal and exhaled NO
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
nasal and exhaled NO
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
subjective assessment of the wound healing
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
subjective assessment of the wound healing
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Time Frame: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Time Frame: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Claus Bachert, MD, PhD, University Hospital Ghent, Belgium
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2011
Primary Completion (Actual)
September 6, 2016
Study Completion (Actual)
February 6, 2017
Study Registration Dates
First Submitted
September 8, 2010
First Submitted That Met QC Criteria
September 9, 2010
First Posted (Estimate)
September 10, 2010
Study Record Updates
Last Update Posted (Actual)
June 15, 2018
Last Update Submitted That Met QC Criteria
June 14, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Paranasal Sinus Diseases
- Nose Diseases
- Polyps
- Sinusitis
- Nasal Polyps
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Doxycycline
Other Study ID Numbers
- 2010/384
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.